OrbiMed β 2025 Investments
19 investments dated 2025 Β· listed companies and verified rows first Β· show all
Clinical-stage company developing novel treatment for recurrent high-grade gliomas
HealthtechChanhassen, US
Jeremy Ling(Executive Officer)Steve Weiner(Executive Officer)Vijay Agarwal(Executive Officer, Director)William Davis(Executive Officer, Director)
BoardImran Eba(Executive Officer)in
Board seatKlaus VeitingerΒ· per SEC Form D
Co-investorsSV Health InvestorsAction Potential Venture Capital Ltd.
Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells.
BiotechHealthtechMedical DevicesCambridge, US
Paul Jaminet(Executive Officer, Director)in
BoardErrik Anderson(Director)Jason Camm(Director)inJonathan Adams(Director)inFabian Hansen(Director)in
Board seatIain DukesΒ· per SEC Form D Β· $28.4M raise Β· filed Sep 2025
Co-investorsGreen Meadow VenturesK5 Global
Bothell, US
Board seatTal ZaksΒ· per SEC Form D Β· $84.8M raise Β· filed Mar 2025
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)Jay Lichter(Director)James Topper(Director)Shelley Chu(Director)
Board seatStephen SquintoΒ· per SEC Form D Β· $15M raise Β· filed Sep 2025
Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesPappas CapitalPfizer Venture Investments
BiotechPhiladelphia, US
William Hinshaw(Executive Officer, Director)Jeff Sacher(Chief Financial Officer)Matthew Ros(Chief Executive Officer, President and Secretary)
BoardGiovanni Mariggi(Director)inMatthew Foy(Director)
Board seatErez ChimovitsΒ· per SEC Form D Β· $46M raise Β· filed May 2025
Co-investors3B Future Health FundMedicxi
BiotechBoston, US
Jotin Marango(Executive Officer)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Sergio Santillana(Executive Officer)Michelle Zhang(Executive Officer)
BoardOtello Stampacchia(Director)in
Board seatIain DukesDavid BonitaΒ· per SEC Form D Β· $75M raise Β· filed Jul 2025
Co-investorsAtlas VentureBiotechnology Value FundForesite CapitalOmega FundsRTW Investments L.P.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.
BiotechHealthtechMedical DevicesPortland, US
Robert Jacks(Executive Officer, Director)David Aaron Katz(Executive Officer, Director)
BoardJonathan Root(Director)inNiall O'Donnell(Director)inZach Scheiner(Director)in
Board seatKlaus VeitingerΒ· per SEC Form D
Co-investorsRA CapitalRiverVest Venture PartnersUS Venture Partners
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in
BoardKristina Burow(Director)inAli Satvat(Director)David Schenkein(Director)in
Board seatDavid BonitaΒ· per SEC Form D
Co-investorsAisling CapitalARCH Venture PartnersCasdin CapitalFidelity InvestmentsGV (Google Ventures)Rock Springs Capital+1 more
Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.
HealthtechMedical DevicesMountain View, US
Matt Brokaw(CEO & President)Derrick Sung(Executive Officer)Matthew Salkeld(Executive Officer)Irina Ridley(Executive Officer)Andre Cheng(Executive Officer)Fred Dinger(Executive Officer, Director)
Co-investorsLaunchCapitalQuesta CapitalTargeted Technology FundsAlly Bridge GroupHorizon
Charm develops open-source tools and libraries for building glamorous command-line interfaces and terminal user experiences, including CLI frameworks, UI components, and integrations with language models.
Developer Tools
Co-investorsBetaworksCavalry VenturesGradient VenturesLOWERCARBONLowercarbon CapitalFuel Capital+4 more
Charm is a payments and savings app that enables users to send money across different platforms (Venmo, Cash App, Zelle) through a unified interface, with funds earning interest when held in the app.
ConsumerCrypto & Web3FintechSocialNew York City, US
Gray Newfield(Founder)inNoah Newfield(Founder)in
Co-investorsY Combinator468 CapitalCavalry VenturesFuel CapitalGradient VenturesKhosla Ventures+2 more
Charm builds open-source tools and libraries for creating user interfaces and applications in the terminal, including command-line interface frameworks, markdown readers, and components for developers.
Developer Tools
Co-investorsMotive ForceNAPCavalry VenturesFuel CapitalGradient VenturesKhosla Ventures+2 more
Curevo Vaccine is a clinical-stage biotech company developing non-mRNA vaccines, with a lead adjuvanted subunit vaccine candidate (amezosvatein/CRV-101) for shingles and chickenpox.
BiotechHealthtech
Co-investorsAdjuvant CapitalRA CapitalSanofi VenturesHBM Healthcare InvestmentsJanus Henderson InvestorsMedicxi
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Quehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)Matthew Fust(Director)Nancy Stagliano, Ph.D.(Director)
Co-investorsRA CapitalWestlake Village BioPartnersNVIDIA
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.
BiotechHealthtech
Co-investorsLongitude CapitalVersant VenturesWellington Management
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).
BiotechHealthtechBerkeley, US
Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)Emily Conley(Executive Officer, Director)
BoardEvan Caplan(Director)inCharlotte McKee(Director)
Co-investors5AM VenturesAtlas VentureQiming Venture Partners USA
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)Jason Hafler(Director)Nancy Stagliano(Director)Michelle Carpenter(Executive Officer)Matthew Fust(Director)Amrit Nagpal(Director)
Co-investorsFrazier Life SciencesRA CapitalSanofi VenturesSofinnova VenturesAgent CapitalBlue Owl Capital+8 more
Treeline provides IT, security, and compliance management services for fast-scaling companies, combining proprietary software automation with human expertise to build modern IT infrastructure that supports business growth.
CybersecurityDeveloper ToolsEnterprise SoftwareSaaSSan Francisco, US
Hussain Kader(Founder)in
Co-investorsAndreessen HorowitzSV AngelHAWKTAILARCH Venture PartnersGV (Google Ventures)
Treeline offers Sails, an MVC web framework for Node.js that lets developers build data-driven APIs and backends in JavaScript, using a bundled ORM (Waterline) and code-generating blueprints.
Cloud ComputingDeveloper ToolsSaaS
Co-investorsSocial StartsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.